دورية أكاديمية
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
| العنوان: | PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients |
|---|---|
| المؤلفون: | D'Incecco, A, Andreozzi, M., Ludovini, V., Rossi, E., Capodanno, A., Landi, L., Tibaldi, C., Minuti, G., Salvini, J., Coppi, E., Chella, A., Filice, M. E., Tornillo, L., Incensati, R. M., Sani, S., Crinò, L., Terracciano, L., Cappuzzo, F., FONTANINI, GABRIELLA |
| المساهمون: | D'Incecco, A, Andreozzi, M., Ludovini, V., Rossi, E., Capodanno, A., Landi, L., Tibaldi, C., Minuti, G., Salvini, J., Coppi, E., Chella, A., Fontanini, Gabriella, Filice, M. E., Tornillo, L., Incensati, R. M., Sani, S., Crinò, L., Terracciano, L., Cappuzzo, F. |
| سنة النشر: | 2015 |
| المجموعة: | ARPI - Archivio della Ricerca dell'Università di Pisa |
| مصطلحات موضوعية: | non-small-cell lung cancer, PD-1, PD-L1, tyrosine kinase inhibitor, Adult, Aged, 80 and over, Antigens, CD274, Carcinoma, Non-Small-Cell Lung, Cohort Studie, Female, Human, Immunohistochemistry, Lung Neoplasm, Male, Middle Aged, Programmed Cell Death 1 Receptor, Retrospective Studie, Cancer Research, Oncology, Medicine (all) |
| الوصف: | BACKGROUND: Agents targeting programmed death-1 receptor (PD-1) and its ligand (PD-L1) are showing promising results in non-small-cell lung cancer (NSCLC). It is unknown whether PD-1/PD-L1 are differently expressed in oncogene-addicted NSCLC. METHODS: We analysed a cohort of 125 NSCLC patients, including 56 EGFR mutated, 29 KRAS mutated, 10 ALK translocated and 30 EGFR/KRAS/ALK wild type. PD-L1 and PD-1 expression were assessed by immunohistochemistry. All cases with moderate or strong staining (2+/3+) in >5% of tumour cells were considered as positive. RESULTS: PD-1 positive (+) was significantly associated with current smoking status (P=0.02) and with the presence of KRAS mutations (P=0.006), whereas PD-L1+ was significantly associated to adenocarcinoma histology (P=0.005) and with presence of EGFR mutations (P=0.001). In patients treated with EGFR tyrosine kinase inhibitors (N=95), sensitivity to gefitinib or erlotinib was higher in PD-L1+ vs PD-L1 negative in terms of the response rate (RR: P=0.01) time to progression (TTP: P<0.0001) and survival (OS: P=0.09), with no difference in PD1+ vs PD-1 negative. In the subset of 54 EGFR mutated patients, TTP was significantly longer in PD-L1+ than in PD-L1 negative (P=0.01). CONCLUSIONS: PD-1 and PD-L1 are differentially expressed in oncogene-addicted NSCLC supporting further investigation of specific checkpoint inhibitors in combination with targeted therapies. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | info:eu-repo/semantics/altIdentifier/pmid/25349974; info:eu-repo/semantics/altIdentifier/wos/WOS:000348280900015; volume:112; issue:1; firstpage:95; lastpage:102; numberofpages:8; journal:BRITISH JOURNAL OF CANCER; http://hdl.handle.net/11568/759619Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84920655625; http://www.nature.com/bjc/index.htmlTest |
| DOI: | 10.1038/bjc.2014.555 |
| الإتاحة: | https://doi.org/10.1038/bjc.2014.555Test http://hdl.handle.net/11568/759619Test http://www.nature.com/bjc/index.htmlTest |
| رقم الانضمام: | edsbas.EBA1F300 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/bjc.2014.555 |
|---|